AUG 13, 2026 · JOURNAL ARTICLE
Comparative Prognostic Value of Systemic Inflammation-Based Biomarkers in Advanced Non-Small Cell Lung Cancer Treated with First-Line Immunotherapy
Biomedicines
A sound retrospective multicenter study identifying independent prognostic biomarkers (CALLY index and SII) in advanced NSCLC treated with first-line immunotherapy, with clear hazard ratios and p-values, but limited by retrospective design and moderate sample size without external validation.
Reported
Clinical benefit rate (high CALLY)82.1%
Clinical benefit rate (low CALLY)59.5%
p-value CBR comparison0.015